

Stanley L Liauw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4646236/publications.pdf>

Version: 2024-02-01

132
papers

4,866
citations

172457

29
h-index

95266

68
g-index

133
all docs

133
docs citations

133
times ranked

5186
citing authors

#	ARTICLE	IF	CITATIONS
1	Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer?. <i>Academic Radiology</i> , 2022, 29, 977-985.	2.5	7
2	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. <i>Annals of Surgical Oncology</i> , 2022, 29, 4583-4592.	1.5	4
3	Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. <i>Journal of Urology</i> , 2022, 207, 1236-1245.	0.4	1
4	Reply by Authors. <i>Journal of Urology</i> , 2022, , 101097JU0000000000000244302.	0.4	0
5	Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5012-5012.	1.6	4
6	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 953-963.	0.8	6
7	Comfort Level of US Radiation Oncology Graduates: Assessment of Transition to Independent Clinical Practice. <i>Journal of Cancer Education</i> , 2021, 36, 278-283.	1.3	6
8	Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 195-195.	1.6	0
9	A prospective clinical and transcriptomic feasibility study of oralâ€œonly hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. <i>Cancer</i> , 2021, 127, 2631-2640.	4.1	3
10	Goals of care discussions: perceptions of radiation and medical oncologists. <i>Supportive Care in Cancer</i> , 2021, 29, 7279-7288.	2.2	4
11	High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure. <i>European Urology</i> , 2021, 80, 147-148.	1.9	0
12	Chemoradiation for Anal Cancer: Clinical Outcomes and Strategies to Optimize the Therapeutic Ratio According to HPV Status. <i>Seminars in Radiation Oncology</i> , 2021, 31, 349-360.	2.2	3
13	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	9
14	Reflections on Anthony Zietman From Gastrointestinal Cancer and Physics Editors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1114-1117.	0.8	0
15	Circulating tumor-tissue modified HPV DNA analysis for molecular disease monitoring after chemoradiation for anal squamous cell carcinoma: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 3155-3162.	1.4	2
16	Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 847-854.	6.3	23
17	Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa081.	2.9	0
18	Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression. <i>Cancer Medicine</i> , 2020, 9, 4667-4675.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 184-191.	1.9	14
20	PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 600.e1-600.e8.	1.6	13
21	18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. <i>Practical Radiation Oncology</i> , 2020, 10, 354-362.	2.1	9
22	A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 1399-1407.	1.4	7
23	A prospective study evaluating oral-only hormonal therapy with radiation for intermediate or high-risk prostate cancer in men age \geq 70 years or with moderate comorbidity.. <i>Journal of Clinical Oncology</i> , 2020, 38, 303-303.	1.6	0
24	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019, 19, 572.	2.6	3
25	Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. <i>European Urology</i> , 2019, 76, 686-692.	1.9	18
26	Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and S \ddot{a} zary syndrome. <i>British Journal of Haematology</i> , 2019, 186, 377-379.	2.5	6
27	The perils of using registry data to compare the survival and cost of radical cystectomy and trimodality therapy in bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S533-S537.	1.4	1
28	Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 382-390.	1.3	3
29	Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e12-e18.	1.9	7
30	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019, 202, 272-281.	0.4	157
31	Regional Influence of Radiation Oncology Residency Training on Job Securement over Two Time Periods. <i>Cureus</i> , 2019, 11, e4495.	0.5	0
32	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. <i>JAMA Oncology</i> , 2018, 4, e175230.	7.1	65
33	Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. <i>Journal of Surgical Education</i> , 2018, 75, 434-441.	2.5	2
34	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018, 74, 99-106.	1.9	28
35	Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 304-313.	0.8	19
36	Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines. <i>Advances in Radiation Oncology</i> , 2018, 3, 339-345.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 471.e11-471.e18.	1.6	9
38	Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. <i>PLoS ONE</i> , 2018, 13, e0194234.	2.5	6
39	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 24-24.	1.6	0
40	High-risk Prostate Cancer Treated With Dose-escalated RT. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 348-352.	1.3	5
41	Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 612-620.	1.3	10
42	Pancreatic, Rectal, and Liver Cancers: Out With the Old, In With the New. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 643-650.	0.8	0
43	Radiation oncology residency selection: A postgraduate evaluation of factor importance and survey of variables associated with job securement. <i>Practical Radiation Oncology</i> , 2017, 7, 425-432.	2.1	21
44	ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 1-10.	1.3	10
45	The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update. <i>Current Urology Reports</i> , 2017, 18, 50.	2.2	5
46	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. <i>Advances in Radiation Oncology</i> , 2017, 2, 437-454.	1.2	21
47	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2017, 16, 266-276.	0.5	26
48	Managing Cancer Relapse After Radical Prostatectomy. <i>Urologic Clinics of North America</i> , 2017, 44, 597-609.	1.8	1
49	A Pancreatic Predicament. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 296-297.	0.8	6
50	Gastrointestinal Cancers: Timing Is Everything. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1051-1058.	0.8	0
51	Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 306-312.	0.8	27
52	External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 740-746.	0.8	7
53	ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. <i>Advances in Radiation Oncology</i> , 2017, 2, 62-84.	1.2	30
54	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9-9.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. Journal of Clinical Oncology, 2017, 2017, 9-9.	1.6	0
56	External validation and optimization of international consensus clinical target volumes for adjuvant radiation in bladder cancer.. Journal of Clinical Oncology, 2017, 35, 336-336.	1.6	0
57	In Reply to Zaghloul. International Journal of Radiation Oncology Biology Physics, 2016, 95, 855.	0.8	0
58	Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2016, 6, e179-e185.	2.1	9
59	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomyâ€”A Multi-Institutional Observational Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1046-1053.	0.8	47
60	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. Journal of Clinical Oncology, 2016, 34, 3648-3654.	1.6	296
61	Gastrointestinal Cancersâ€”Changing the Standard forâ€”Rectal Cancer and Establishing a New Standard forâ€”Liverâ€”Tumors. International Journal of Radiation Oncology Biology Physics, 2016, 95, 930-936.	0.8	1
62	Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 416.e15-416.e21.	1.6	17
63	A Prostate Fossa Contouring Instructional Module: Implementation and Evaluation. Journal of the American College of Radiology, 2016, 13, 835-841.e1.	1.8	10
64	ACR Appropriateness Criteria Renal Cell Carcinoma Staging. Journal of the American College of Radiology, 2016, 13, 518-525.	1.8	32
65	Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1031-1039.	0.8	33
66	Key New Studies in Gastric and Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 475-481.	0.8	1
67	Management of Low-Stage Testicular Seminoma. Urologic Clinics of North America, 2015, 42, 287-298.	1.8	8
68	Randomized Trials and New Directions inâ€”Gastrointestinal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 459-464.	0.8	3
69	The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2015, 5, e223-e228.	2.1	8
70	Image-guided radiation therapy for prostate cancer: A computed tomographyâ€”based assessment of fiducial marker migration between placement and 7 days. Practical Radiation Oncology, 2015, 5, 241-247.	2.1	10
71	Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes. PLoS ONE, 2015, 10, e0141639.	2.5	12
72	The role of the radiation oncologist in goals-of-care discussions.. Journal of Clinical Oncology, 2015, 33, 42-42.	1.6	26

#	ARTICLE	IF	CITATIONS
73	Clinical Outcomes for Gastric Cancer following Adjuvant Chemoradiation Utilizing Intensity Modulated versus Three-Dimensional Conformal Radiotherapy. <i>PLoS ONE</i> , 2014, 9, e82642.	2.5	22
74	Considering the role of radiation therapy for gastrointestinal stromal tumor. <i>OncoTargets and Therapy</i> , 2014, 7, 713.	2.0	16
75	Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. <i>Cancer Medicine</i> , 2014, 3, 954-961.	2.8	18
76	Combined-modality Therapy for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 122-125.	1.3	2
77	Herpes zoster and radiation therapy: What radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster. <i>Practical Radiation Oncology</i> , 2014, 4, 58-64.	2.1	5
78	Oncology Scan—Novel Treatment Strategies for Gastrointestinal Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 699-703.	0.8	4
79	Effects of aspirin on cancer initiation and progression. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 115-117.	2.4	3
80	Toxicity After External Beam Radiotherapy for Prostate Cancer: An Analysis of Late Morbidity in Men With Diabetes Mellitus. <i>Urology</i> , 2013, 81, 1196-1201.	1.0	29
81	Validation of Normal Tissue Complication Probability Predictions in Individual Patient: Late Rectal Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1103-1109.	0.8	6
82	Evaluation of the Prostate Bed for Local Recurrence After Radical Prostatectomy Using Endorectal Magnetic Resonance Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 378-384.	0.8	77
83	Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity modulated radiation therapy. <i>Practical Radiation Oncology</i> , 2013, 3, e1-e9.	2.1	19
84	Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. <i>Practical Radiation Oncology</i> , 2013, 3, 138-144.	2.1	19
85	New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. <i>Science Translational Medicine</i> , 2013, 5, 173sr2.	12.4	197
86	Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 589-595.	1.3	87
87	Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. <i>Cancer</i> , 2013, 119, 2807-2814.	4.1	20
88	Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. <i>OncoTargets and Therapy</i> , 2013, 6, 1097.	2.0	2
89	Aspirin Use and the Risk of Prostate Cancer Mortality in Men Treated With Prostatectomy or Radiotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 3540-3544.	1.6	98
90	Late Toxicity After Intensity-Modulated Radiation Therapy for Localized Prostate Cancer: An Exploration of Dose-Volume Histogram Parameters to Limit Genitourinary and Gastrointestinal Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 235-241.	0.8	97

#	ARTICLE	IF	CITATIONS
91	High-Dose Radiotherapy With or Without Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer: Cancer Control and Toxicity Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1473-1479.	0.8	13
92	Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: A report of total setup error, required PTV expansion, and dosimetric implications. <i>Radiotherapy and Oncology</i> , 2012, 103, 270-274.	0.6	27
93	Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 202-207.	1.3	0
94	Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence. <i>Annals of Surgical Oncology</i> , 2012, 19, 2471-2476.	1.5	22
95	Radiation dose ≥ 54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. <i>Radiation Oncology</i> , 2012, 7, 156.	2.7	15
96	Prolongation of Total Treatment Time Because of Infrequently Missed Days of Treatment Is Not Associated With Inferior Biochemical Outcome After Dose-Escalated Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 751-757.	0.8	9
97	Prostate-Specific Antigen Halving Time While on Neoadjuvant Androgen Deprivation Therapy Is Associated With Biochemical Control in Men Treated With Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1022-1028.	0.8	10
98	External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men With High International Prostate Symptom Scores (IPSS). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1080-1086.	0.8	42
99	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. <i>Open Access Journal of Urology</i> , 2011, 3, 95-104.	0.3	1
100	A Surveillance, Epidemiology, and End Results Registry Analysis of Prostate Cancer Modality Time Trends by Age. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 619-623.	1.3	14
101	External Beam Radiation Therapy After Transurethral Resection of the Prostate: A Report on Acute and Late Genitourinary Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1060-1065.	0.8	37
102	Late rectal toxicity after prostate brachytherapy: Influence of supplemental external beam radiation on dose-volume histogram analysis. <i>Brachytherapy</i> , 2010, 9, 131-136.	0.5	16
103	The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. <i>Cancer</i> , 2010, 116, 1820-1826.	4.1	50
104	External Beam Radiotherapy for Prostate Cancer Patients on Anticoagulation Therapy: How Significant is the Bleeding Toxicity?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 755-760.	0.8	67
105	Dose-Escalated Radiotherapy for High-Risk Prostate Cancer: Outcomes in Modern Era With Short-Term Androgen Deprivation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 125-130.	0.8	14
106	Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer. <i>Scientific World Journal</i> , The, 2010, 10, 1854-1869.	2.1	10
107	Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2653-2659.	1.6	146
108	Reply to H.W. Daniell and to L. Azoulay and S. Suissa. <i>Journal of Clinical Oncology</i> , 2010, 28, e645-e646.	1.6	0

#	ARTICLE	IF	CITATIONS
109	The role of radiotherapy in locally advanced pancreatic carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 437-447.	17.8	36
110	Prostate Cancer Modality Time Trend Analyses From 1973 to 2004. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 168-172.	1.3	23
111	Biochemical Control and Toxicity after Intensity-Modulated Radiation Therapy for Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 201-206.	1.9	25
112	Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009, 6, 38-46.	1.7	11
113	Dose-escalated radiation therapy for intermediate-risk prostate cancer. <i>Cancer</i> , 2009, 115, 1784-1790.	4.1	17
114	Lymph node-positive head and neck cancer treated with definitive radiotherapy. <i>Cancer</i> , 2008, 112, 1076-1082.	4.1	55
115	Salvage Radiotherapy After Postprostatectomy Biochemical Failure: Does Pretreatment Radioimmunoscintigraphy Help Select Patients with Locally Confined Disease?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1316-1321.	0.8	12
116	The Use of Capecitabine in the Combined-Modality Therapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 99-104.	2.3	3
117	A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. <i>Urology</i> , 2008, 72, 1298-1302.	1.0	103
118	Age and Grade Trends in Prostate Cancer (1974-2003). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 375-378.	1.3	41
119	Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2007, 25, 2035-2041.	1.6	836
120	Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter Experience. <i>Journal of Clinical Oncology</i> , 2007, 25, 4581-4586.	1.6	252
121	The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients. <i>Clinical Medicine and Research</i> , 2007, 5, 123-131.	0.8	8
122	Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: Salvage in the dissected or undissected neck. <i>Head and Neck</i> , 2007, 29, 715-719.	2.0	28
123	Radiotherapy after subtotally resected or recurrent ganglioglioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 244-247.	0.8	46
124	Postradiotherapy Neck Dissection for Lymph Node-Positive Head and Neck Cancer: The Use of Computed Tomography to Manage the Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 1421-1427.	1.6	160
125	Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 669-673.	0.8	122
126	Definitive radiotherapy for head-and-neck cancer with radiographically positive retropharyngeal nodes: Incomplete radiographic response does not necessarily indicate failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1017-1021.	0.8	6

#	ARTICLE	IF	CITATIONS
127	Whole-abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1440-1445.	0.8	3
128	The Effect of Intravenous Contrast on Intensity-Modulated Radiation Therapy Dose Calculations for Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 456-459.	1.3	26
129	Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1325.	7.4	588
130	Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease. <i>Cancer</i> , 2004, 100, 920-928.	4.1	62
131	Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. <i>Urology</i> , 2003, 61, 1204-1210.	1.0	55
132	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. <i>Research and Reports in Urology</i> , 0, Volume 3, 95-104.	1.0	0